TCIM
GNMK

TIAA CREF Investment Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

TIAA CREF Investment Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.3M Buy
183,051
+28,400
+18% +$187K ﹤0.01% 2201
2018
Q4 		$752K Sell
154,651
-1,189
-0.8% -$6.19K ﹤0.01% 2397
2018
Q3 		$1.15M Sell
155,840
-6,108
-4% -$44.8K ﹤0.01% 2367
2018
Q2 		$1.03M Sell
161,948
-5,256
-3% -$34.7K ﹤0.01% 2482
2018
Q1 		$910K Sell
167,204
-8,356
-5% -$41.5K ﹤0.01% 2488
2017
Q4 		$732K Buy
175,560
+4,829
+3% +$29.1K ﹤0.01% 2616
2017
Q3 		$1.64M Buy
170,731
+1,843
+1% +$19.1K ﹤0.01% 2273
2017
Q2 		$2M Buy
168,888
+1,268
+0.8% +$16.2K ﹤0.01% 2177
2017
Q1 		$2.15M Sell
167,620
-7,896
-4% -$95K ﹤0.01% 2100
2016
Q4 		$2.15M Buy
175,516
+2,081
+1% +$24.7K ﹤0.01% 2150
2016
Q3 		$2.05K Buy
173,435
+6,375
+4% +$61.5K ﹤0.01% 2159
2016
Q2 		$1.45M Sell
167,060
-4,767
-3% -$32.7K ﹤0.01% 2316
2016
Q1 		$906K Sell
171,827
-5,572
-3% -$31K ﹤0.01% 2527
2015
Q4 		$1.38M Sell
177,399
-6,354
-3% -$48.8K ﹤0.01% 2382
2015
Q3 		$1.45M Buy
183,753
+36,895
+25% +$341K ﹤0.01% 2343
2015
Q2 		$1.33M Buy
146,858
+475
+0.3% +$4.79K ﹤0.01% 2540
2015
Q1 		$1.9M Hold
146,383
– – ﹤0.01% 2245
2014
Q4 		$1.99M Sell
146,383
-10,275
-7% -$115K ﹤0.01% 2240
2014
Q3 		$1.41M Sell
156,658
-1,362
-0.9% -$14.7K ﹤0.01% 2443
2014
Q2 		$2.14M Buy
158,020
+20,385
+15% +$213K ﹤0.01% 2268
2014
Q1 		$1.37M Sell
137,635
-2,880
-2% -$35.8K ﹤0.01% 2466
2013
Q4 		$1.87M Buy
140,515
+5,170
+4% +$62.8K ﹤0.01% 2299
2013
Q3 		$1.64M Buy
135,345
+16,510
+14% +$177K ﹤0.01% 2336
2013
Q2 		$1.23M Buy
+118,835
New +$1.64M ﹤0.01% 2468

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TIAA CREF Investment Management's GNMK Position: Q1 2019 in Review

TIAA CREF Investment Management increased its GenMark Diagnostics, Inc (GNMK) stake by 18% in Q1 2019, buying an estimated $187K and bringing the position to 183,051 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2201.

TIAA CREF Investment Management first reported a position in GNMK in Q2 2013 and has held it in 24 quarters since. The position peaked at $2.15M in Q1 2017. 106 funds tracked by Wall St. Rank hold GNMK as of Q1 2019.

  • TIAA CREF Investment Management held 183,051 shares of GenMark Diagnostics, Inc worth $1.3M as of Q1 2019.
  • TIAA CREF Investment Management bought 28,400 GenMark Diagnostics, Inc shares in Q1 2019, an estimated $187K.
  • GenMark Diagnostics, Inc made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2201 holding.
  • TIAA CREF Investment Management first reported a position in GenMark Diagnostics, Inc in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's GenMark Diagnostics, Inc position peaked at $2.15M in Q1 2017.
  • 106 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.